Cited by 826Atrial Fibrillation Management and OutcomesBlood Pressure and Hypertension StudiesCardiac electrophysiology and arrhythmias

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol

Open access

Wachtell, Kristian, Lehto, Mika, Gerdts, Eva, Olsen, Michael H., Hornestam, Björn, Dahlöf, Björn, Ibsen, Hans, Julius, Stevo, Kjeldsen, Sverre E., Lindholm, Lars H., Nieminen, Markku S., Devereux, Richard B.·2005·Journal of the American College of Cardiology

DOI 10.1016/j.jacc.2004.10.068

Open this paper in CoChat — free account Open PDF

Abstract

Objectives This study was designed to evaluate whether different antihypertensive treatment regimens with similar blood pressure reduction have different effects on new-onset atrial fibrillation (AF).Background It is unknown whether angiotensin II receptor blockade is better than beta-blockade in preventing new-onset AF.Methods In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study 9,193 hypertensive patients and patients with electrocardiogram-documented left ventricular hypertrophy were randomized to once-daily losartan- or atenolol-based antihypertensive therapy. Electrocardiograms were Minnesota coded centrally, and 8,851 patients without AF by electrocardiogram or history, who were thus at risk of developing AF, were followed for 4.8 +/- 1.0 years.Results New-onset AF occurred in 150 patients randomized to losartan versus 221 to atenolol (6.8 vs. 10.1 per 1,000 person-years; relative risk 0.67, 95% confidence interval [CI] 0.55 to 0.83, p < 0.001) despite similar blood pressure reduction. Patients receiving losartan tended to stay in sinus rhythm longer (1,809 +/- 225 vs. 1,709 +/- 254 days from baseline, p = 0.057) than those receiving atenolol. Moreover, patients with new-onset AF had two-, three- and fivefold increased rates, respectively, of cardiovascular events, stroke, and hospitalization for heart failure. There were fewer composite end points (n = 31 vs. 51, hazard ratio = 0.60, 95% CI 0.38 to 0.94, p = 0.03) and strokes (n = 19 vs. 38, hazard ratio = 0.49, 95% CI 0.29 to 0.86, p = 0.01) in patients who developed new-onset AF in the losartan compared to the atenolol treatment arm of the study. Furthermore, Cox regression analysis showed that losartan (21% risk reduction) and new-onset AF both independently predicted stroke even when adjusting for traditional risk factors.Conclusions Our novel finding is that new-onset AF and associated stroke were significantly reduced by losartan- compared to atenolol-based antihypertensive treatment with similar blood pressure reduction.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2004.10.068

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Self-citation
An updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834
A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study
Stewart, S., Hart, C. L., Hole, D. J., & McMurray, J. J. V. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01236-6 · Cited by 1,562
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary
Fuster, V., Rydén, L., ASINGER, R. W., Cannom, D. S., Crijns, H. J. G. M., Frye, R. L., Halperin, J. L., Kay, G. N., Klein, W. W., Lévy, S., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01587-x · Cited by 1,362
Left Atrial Size and the Risk of Stroke and Death
Benjamin, E. J., D’Agostino, R. B., Belanger, A. J., Wolf, P. A., & Levy, D. A. (1995) · Circulation · doi:10.1161/01.cir.92.4.835 · Cited by 1,058
Effects of Angiotensin-Converting Enzyme Inhibition on the Development of the Atrial Fibrillation Substrate in Dogs With Ventricular Tachypacing–Induced Congestive Heart Failure
Li, D., Shinagawa, K., Pang, L., Leung, T. K., Cardin, S., Wang, Z., & Nattel, S. (2001) · Circulation · doi:10.1161/hc4601.099402 · Cited by 702
Use of Irbesartan to Maintain Sinus Rhythm in Patients With Long-Lasting Persistent Atrial Fibrillation: A Prospective and Randomized Study
Madrid, A. H., Bueno, M. G., Rebollo, J. M. G., Marín, I., Peña, G., Bernal, E., Rodriguez, A., Cano, L., Cano, J. M., Cabeza, P., et al. (2002) · Circulation · doi:10.1161/01.cir.0000022665.18619.83 · Cited by 685
Trandolapril Reduces the Incidence of Atrial Fibrillation After Acute Myocardial Infarction in Patients With Left Ventricular Dysfunction
Pedersen, O. D., Bagger, H., Køber, L., & Torp-Pedersen, C. T. (1999) · Circulation · doi:10.1161/01.cir.100.4.376 · Cited by 656
Enalapril Decreases the Incidence of Atrial Fibrillation in Patients With Left Ventricular Dysfunction
Vermès, E., Tardif, J., Bourassa, M. G., Racine, N., Lévesque, S., White, M., Guerra, P. G., & Ducharme, A. (2003) · Circulation · doi:10.1161/01.cir.0000072793.81076.d4 · Cited by 575
Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation
Kumagai, K., Nakashima, H., Urata, H., Gondo, N., Arakawa, K., & Saku, K. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00464-9 · Cited by 472

Flagged first, then by citations

Show all 27 references

Sorted by citations

Items 501–600 of 819

The Influence of Risk Factor Modification on Atrial Fibrillation Outcomes and Their Impact on the Success of Catheter Ablation
Chandan, N., Ashok, V., Hwang, T., Lim, V. G., Lachlan, T., Eftekhari, H., McGregor, G., & Osman, F. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm27175 · Cited by 7
Blood pressure targets, medication considerations and special concerns in elderly hypertension: Focus on atherosclerotic cardiovascular diseases, atrial fibrillation, heart failure, and aortic stenosis
Hsu, R.-Y., Lo, H.-Y., Chen, C.-H., Wu, Y.-J., Chan, D., Wu, C., Wang, T., Kao, H., Sun, W., Lin, Y., et al. (2025) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2025.05.007 · Cited by 8
Inflammation and Atrial Fibrillation
Endoh, Y., Endoh, I., Geczy, C. L., Nakagomi, A., Kusama, Y., & Atarashi, H. (2011) · Journal of Arrhythmia · doi:10.1016/s1880-4276(11)80017-7 · Cited by 7
Effect of antihypertensive agents on the risk of new-onset and recurrent atrial fibrillation: a Bayesian network meta-analysis of randomized controlled trials
Gewehr, D. M., Carvalho, P. E. P., Martignoni, F., Nogueira, A., Gomes, C. P., Navalha, D. D. P., Pirez, J., Melo, L., de Mesquita, Y. L. L., Braga, M. A. P., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf335 · Cited by 7
Combined effects of up- and downstream therapies on atrial fibrillation in a canine rapid stimulation model
Fukaya, H., Niwano, S., Niwano, H., Masaki, Y., Kiryu, M., Hirasawa, S., Satoh, D., Moriguchi, M., & Izumi, T. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.12.008 · Cited by 7
Angiotensin II does not acutely regulate conduction velocity in rat atrial tissue
Olsen, K. B., Braunstein, T. H., Sørensen, C. M., Axelsen, L. N., Holstein‐Rathlou, N., & Nielsen, M. S. (2011) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365513.2011.589009 · Cited by 7
Disease monitoring of Primary Aldosteronism
Rossi, G. P., Cesari, M., Lenzini, L., & Seccia, T. M. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101417 · Cited by 7
Die Behandlung von Vorhofflimmern im Alltag
Meinertz, T., & Willems, S. (2008) · Der Internist · doi:10.1007/s00108-008-2152-6 · Cited by 7
Upstream Therapy for Atrial Fibrillation
Kumagai, K. (2007) · Circulation Journal · doi:10.1253/circj.71.a75 · Cited by 7
Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention
Talbert, R. L. (2010) · Journal of the American Pharmacists Association · doi:10.1331/japha.2010.09234 · Cited by 7
Angiotensin‐(1–7) Prevent Atrial Tachycardia Induced Sodium Channel Remodeling
Wang, X., & Li, G. (2014) · Pacing and Clinical Electrophysiology · doi:10.1111/pace.12427 · Cited by 7
Contribution of the left atrial remodeling to the elevated pulmonary capillary wedge pressure in patients with WHO Group II pulmonary hypertension
Purga, S. L., Karas, M. G., Horn, E. M., & Torosoff, M. T. (2018) · Journal of Echocardiography · doi:10.1007/s12574-018-0410-8 · Cited by 7
Angiotensin II receptor type 1 is upregulated in atrial tissue of patients with rheumatic valvular disease with atrial fibrillation
Cong, H., Li, X., Ma, L., Jiang, H., Mao, Y., & Xu, M. (2010) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2009.10.035 · Cited by 7
Reviewing the future of renin-angiotensin system blockade: The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the prevention of atrial fibrillation
Ducharme, A., & Schiffrin, E. L. (2010) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(10)71170-3 · Cited by 7
Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade
Parvanova, A. I., Chiurchiu, C. R., Ruggenenti, P. L., & Remuzzi, G. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.11.1931 · Cited by 7
Últimas novedades en hipertensión arterial
Bertoméu, V., Blasco, P. M., Arcos, F. S., & Ramos, P. M. (2006) · Revista Española de Cardiología · doi:10.1157/13084451 · Cited by 7
Comparative Effects of Olmesartan and Azelnidipine on Atrial Structural Remodeling in Spontaneously Hypertensive Rats
Okamura, K., 伊藤, 正., Tanaka, K., Chinushi, M., Adachi, T. K., Mitsuma, W., Hirono, S., Nakazawa, M., Kodama, M., & Aizawa, Y. (2009) · Pharmacology · doi:10.1159/000218103 · Cited by 7
Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update
Chrysant, S. G., Dimas, B., & Shiraz, M. F. (2007) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1002241 · Cited by 7
Focus on renin–angiotensin system modulation and atrial fibrillation control after GISSI AF results
Durin, O., Pedrinazzi, C., & Inama, G. (2010) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e32833cdd6f · Cited by 7
Atrial Fibrillation, Maybe it Is Not So Lone?⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
Wachtell, K. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.010 · Cited by 7
Self-citation
Hypertension and atrial fibrillation: the clinical impact of hypertension on perioperative outcomes of atrial fibrillation ablation and its optimal control for the prevention of recurrence
Kamioka, M., Narita, K., Watanabe, T., Watanabe, H., Makimoto, H., Okuyama, T., Yokota, A., Komori, T., Kabutoya, T., Imai, Y., et al. (2024) · Hypertension Research · doi:10.1038/s41440-024-01796-3 · Cited by 6
Racial Differences in Incident Atrial Fibrillation Among Hypertensive Patients During Antihypertensive Therapy
Okin, P. M., Bang, C. N., Wachtell, K., Hille, D. A., Kjeldsen, S. E., Julius, S., Dahlöf, B., & Devereux, R. B. (2014) · American Journal of Hypertension · doi:10.1093/ajh/hpu006 · Cited by 6
Self-citation
Arterial hypertension and atrial fibrillation
Cameli, M., Mandoli, G. E., Ambrosio, G., Cerbai, E., Coiro, S., Emdin, M., Marcucci, R., Morrone, D., Palazzuoli, A., Savino, K., et al. (2017) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000607 · Cited by 6
Current Evidence on Prevention of Atrial Fibrillation: Modifiable Risk Factors and the Effects of Risk Factor Intervention
Akboğa, M. K., İnanç, İ. H., Keskin, M., Şabanoğlu, C., & Görenek, B. (2021) · Cardiology in Review · doi:10.1097/crd.0000000000000426 · Cited by 6
Arterial Stiffness is Associated with Tissue Doppler Atrial Conduction Times and P Wave Dispersion in Hypertensive Patients
Elsherbiny, I. A. (2012) · Internal Medicine · doi:10.2169/internalmedicine.51.6345 · Cited by 6
Beneficial effects of losartan for prevention of paroxysmal atrial fibrillation in patients with sick sinus syndrome: analysis with memory function of pacemaker
Takii, E., Inage, T., Yoshida, T., Ohe, M., Gondo, T., Haraguchi, G., Ito, S., Kumanomido, J., Imaizumi, T., & Fukuomoto, Y. (2015) · Heart and Vessels · doi:10.1007/s00380-015-0627-7 · Cited by 6
Long-term effects of irbesartan on plasma aldosterone concentration and left atrial volume in hypertensive patients
Masaki, M., Komamura, K., Goda, A., Hirotani, S., Otsuka, M., Nakabo, A., Fukui, M., Fujiwara, S., Sugahara, M., Lee‐Kawabata, M., et al. (2013) · Journal of Cardiology · doi:10.1016/j.jjcc.2013.08.004 · Cited by 6
Catheter ablation vs. amiodarone plus losartan for prevention of atrial fibrillation recurrence in patients with paroxysmal atrial fibrillation
Lan, X., Su, L., Ling, Z., Liu, Z., Wu, J., Yang, X., Zrenner, B., & Yin, Y. (2009) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2009.02160.x · Cited by 6
Medical management of atrial fibrillation
Hersi, A. S., & Wyse, D. G. (2006) · Current Cardiology Reports · doi:10.1007/s11886-006-0070-6 · Cited by 6
Non-Invasive Pulmonary Capillary Wedge Pressure Assessment on Speckle Tracking Echocardiography as a Predictor of New-Onset Non-Valvular Atrial Fibrillation ― Four-Year Prospective Study (NIPAF Study) ―
Kawasaki, M., Tanaka, R., 吉田明弘, Nagaya, M., Minatoguchi, S., Yoshizane, T., Watanabe, T., Kanamori, H., Ono, K., Hirose, T., et al. (2018) · Circulation Journal · doi:10.1253/circj.cj-18-0799 · Cited by 6
Paradigm shifts in pathophysiology and management of atrial fibrillation—a tale of the RACE trials in the Netherlands
Crijns, H. J. G. M., & Gelder, I. C. V. (2020) · Netherlands Heart Journal · doi:10.1007/s12471-020-01476-0 · Cited by 6
Atrial fibrillation complicating congestive heart failure: Electrophysiological aspects and its deleterious effect on cardiac resynchronization therapy
Centurión, O. A. (2009) · Journal of Atrial Fibrillation · doi:10.4022/jafib.v1i7.538 · Cited by 7
Acetylcholine-regulated K+ current remodelling in the atrium after myocardial infarction and valsartan administration
Zhao, Q., Huang, C., Jiang, H., Okello, E., Wang, X., Tang, Y.-H., & Li, G.-S. (2009) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(09)70069-8 · Cited by 6
Drugs that interact with cardiac electro-mechanics: Old and new targets for treatment
Kirchhof, P. F., Fortmueller, L., Waldeyer, C., Breithardt, G., & Fabritz, L. (2008) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2008.02.003 · Cited by 6
The Importance of Integrated Risk Management When Treating Patients with Hypertension: Benefits of Angiotensin II Receptor Antagonist Therapy
Ruilope, L. M., & Segura, J. (2008) · Clinical and Experimental Hypertension · doi:10.1080/10641960802279066 · Cited by 6
Pathophysiology of atrial fibrillation: Insights into the renin–angiotensin system
Heuzey, J. L., Marijon, É., Chachoua, K., Waintraub, X., Lepillier, A., Otmani, A., Lavergne, T., & Pornin, M. (2008) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2008.09.015 · Cited by 6
Prevención de la fibrilación auricular en el paciente hipertenso
Alonso, V. B., von Wichmann, M. D. L. F., & Payeras, A. C. (2007) · Medicina Clínica · doi:10.1157/13098021 · Cited by 6
Association between the use of non-antiarrhythmic drugs and postoperative atrial fibrillation
Özaydın, M., Türker, Y., Peker, O., Erdoğan, D., Varol, E., Doğan, A., & İbrişim, E. (2009) · International Journal of Cardiology · doi:10.1016/j.ijcard.2009.02.029 · Cited by 6
Blockade of Brain Angiotensin II Type 1 Receptor Inhibits the Development of Atrial Fibrillation in Hypertensive Rats
Nagayama, T., Hirooka, Y., Kishi, T., Mukai, Y., Inoue, S., Takase, S., Takemoto, M., Chishaki, A. S., & Sunagawa, K. (2014) · American Journal of Hypertension · doi:10.1093/ajh/hpu196 · Cited by 6
Current Role of Medical Therapy for Prevention or Termination of Atrial Fibrillation
Baranchuk, A. M., Morillo, C. A., Thoenes, M., Ventura, R., & Connolly, S. J. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-163-5_13 · Cited by 6
Cerebral White Matter Lesions, Risk of Stroke and Cerebrovascular Protection with Angiotensin Receptor Blockers
de la Sierra, A., & Sierra, C. (2006) · Current Drug Therapy · doi:10.2174/157488506775268452 · Cited by 6
Left Atrial Reverse Remodeling in Patients Supported With Durable Left Ventricular Assist Devices and Clinical Implications
Kyriakopoulos, C. P., Sideris, K., Taleb, I., Maneta, E., Tseliou, E., Aadland, J., Baird, A. S., Bonios, M. J., Nelson, M., Dranow, E., et al. (2025) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.012807 · Cited by 5
Usefulness of Blood–Urea–Nitrogen to Serum Albumin Ratio for In-hospital Mortality Predictions in Atrial Fibrillation Patients Admitted to the Intensive Care Unit: A Retrospective Analysis From MIMIC-IV Database
Xie, H., Luo, Q., & Huang, T. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm36596 · Cited by 5
Aging China's cardiac challenge: Projected growth of atrial arrhythmia cases and healthcare preparedness through 2045 — A global burden disease analysis
Xiong, J., Chen, S., Wu, X., Wang, B.-Y., You, B., & Yu, R. (2025) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.70089 · Cited by 5
Inflammatory markers in paroxysmal atrial fibrillation and the protective role of renin-angiotensin-aldosterone system inhibitors.
Roşian, Ş. H., Roşianu, A., Aldica, M., Capalneanu, R., & Buzoianu, A. D. (2013) · Europe PMC (PubMed Central) · Cited by 5
Low plasma renin activity is associated with “Apparently” idiopathic atrial fibrillation
Shen, Y., Ma, G., Sun, M., Li, M., & Chen, M. (2023) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2023.101286 · Cited by 5
Effects of eprosartan on target organ protection
de la Sierra, A. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.1.79 · Cited by 5
Carvedilol is Effective and Safe in Combination With Bepridil for Persistent Atrial Fibrillation and Decreases the QT Prolongation Induced by Bepridil Therapy
Kawamura, M., Munetsugu, Y., Tanno, K., & Kobayashi, Y. (2012) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3182790692 · Cited by 5
During ablation for atrial fibrillation, is simultaneous renal artery ablation appropriate?
Hogarth, A. J., Dobson, L. E., & Tayebjee, M. H. (2013) · Journal of Human Hypertension · doi:10.1038/jhh.2013.75 · Cited by 5
Preventive effect of renin-angiotensin system inhibitors on new-onset atrial fibrillation in hypertensive patients: a propensity score matching analysis
Horio, T., Akiyama, M., Iwashima, Y., Yoshihara, F., Nakamura, S., Tokudome, T., Okutsu, M., Tanaka, H., Komatsubara, I., Okimoto, N., et al. (2016) · Journal of Human Hypertension · doi:10.1038/jhh.2016.95 · Cited by 5
Prognostic factors of clinical endpoints in elderly patients with atrial fibrillation during a 2-year follow-up in China
Wang, H., Wang, H., Chen, Y.-D., Tao, T., Guo, Y., Zhao, X., Liu, H.-B., & Wang, Y. (2017) · Medicine · doi:10.1097/md.0000000000007679 · Cited by 5
Addressing Extracardiac Risk Factors to Improve Atrial Fibrillation Treatment Outcomes
Andrade, J. G., & Macle, L. (2019) · Journal of Innovations in Cardiac Rhythm Management · doi:10.19102/icrm.2019.101103 · Cited by 5
Oxidative Stress and Atrial Fibrillation
Sovari, A. A., & Dudley, S. C. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-600-9_19 · Cited by 5
Treatment of Hypertension in the Patient with Cardiovascular Disease * *Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ACS, acute coronary syndromes; AF, atrial fibrillation; MI, myocardial infarction; ARB, angiotensin II type 1 receptor blocker; BB, beta-adrenergic receptor blocker; BP, blood pressure; CCB, calcium channel blocker; CVD, cardiovascular disease; CHD, coronary heart disease; DM, diabetes mellitus; DBP, diastolic blood pressure; ESRD, end-stage renal disease; HF, heart failure; HTN, hypertension; ISH, isolated systolic hypertension; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; LVH, left ventricular hypertrophy; PP, pulse pressure; PAD, peripheral arterial disease; PWV, pressure wave velocity; RAAS, renin-angiotensin-aldosterone system; RWT, relative wall thickness; SBP, systolic blood pressure; U.S., United States.
Chrysant, G. S., & Oparil, S. (2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-3358-5.50040-1 · Cited by 5
Olmesartan Reduces New-onset Atrial Fibrillation and Atrial Fibrillation Burden after Dual-chamber Pacemaker Implantation in Atrioventricular Block Patients
Zhang, H., Pan, C., Zhang, J., Zhu, L., Huang, K., Zhong, Y., & Hu, Z. (2016) · Chinese Medical Journal · doi:10.4103/0366-6999.189924 · Cited by 5
Renin Angiotenin Blocker Pre-treatment and Recurrence After Pulmonary Vein Isolation in Patients with Paroxysmal and Persistent Atrial Fibrillation.
Rosen, B. D., AKOUM, N. W., Burgon, N. S., Vergara, G., MARROUCHE, N. F., & Bader, F. M. (2013) · Europe PMC (PubMed Central) · doi:10.4022/jafib.898 · Cited by 5
Blood Pressure Control versus Atrial Fibrillation Management in Stroke Prevention
Savoia, C., Sada, L., & Volpe, M. (2015) · Current Hypertension Reports · doi:10.1007/s11906-015-0553-1 · Cited by 5
Inhibition of the Renin-Angiotensin System and Atrial Fibrillation in Heart Failure
Palardy, M., & Ducharme, A. (2005) · Heart Drug · doi:10.1159/000089602 · Cited by 5
Can losartan prevent new-onset atrial fibrillation in hypertensive patients more effectively than atenolol?
Nattel, S. (2005) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0247 · Cited by 5
Preclinical and Clinical Effects of RAS Inhibition with a Focus on Telmisartan
Unger, T. (2012) · ISRN Vascular Medicine · doi:10.5402/2012/712047 · Cited by 5
Rhythm Association and the Heart Rhythm Society Developed in Collaboration With the European Heart Atrial Fibrillation): Committee to Revise the 2001 Guidelines for the Management of Patients With the European Society of Cardiology Committee for Practice Guidelines (Writing Cardiology/American Heart Association Task Force on Practice Guidelines and Fibrillation—Executive Summary: A Report of the American College of ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial
Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, L., Despres, C., Dickstein, K., Lekakis, J. P., McGregor, K., Metra, M., Budaj, A., et al. (2006) · Cited by 5
Pharmacotherapy of atrial fibrillation: an old option with new possibilities
Janko, S., Dorwarth, U., & Hoffmann, E. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.6.913 · Cited by 5
Do we need more than just powerful blood pressure reductions? New paradigms in end-organ protection
Galzerano, D. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s7969 · Cited by 5
Controversies in ablation of atrial fibrillation
Aliot, E., & Ruskin, J. N. (2008) · European Heart Journal Supplements · doi:10.1093/eurheartj/sun030 · Cited by 5
Renin-Angiotensin System and AtrialFibrillation:Understanding the Connection.
Disertori, M., & Quintarelli, S. (2011) · Europe PMC (PubMed Central) · doi:10.4022/jafib.398 · Cited by 5
Highlights of the Year in JACC2005
DeMaria, A. N., Ben‐Yehuda, O., Berman, D. S., Feld, G. K., Ginsburg, G. S., Greenberg, B., Lew, W. Y. W., Sahn, D. J., & Tsimikas, S. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.11.020 · Cited by 5
Use of beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers to prevent atrial fibrillation
Wachtell, K., Devereux, R. B., & Lyle, P. A. (2006) · Current Cardiology Reports · doi:10.1007/s11886-006-0075-1 · Cited by 5
Self-citation
Optimising stroke prevention in non-valvular atrial fibrillation
Éderhy, S., & Cohen, A. A. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.15.2079 · Cited by 5
The effect of angiotensin receptor blockers for preventing atrial fibrillation
Wachtell, K., Devereux, R. B., & Lyle, P. A. (2007) · Current Hypertension Reports · doi:10.1007/s11906-007-0051-1 · Cited by 5
Self-citation
Clinical practicality and predictive value of transoesophageal echocardiography in early cardioversion of atrial fibrillation
Strandberg, M., Raatikainen, M. J. P., Niemelä, M. J., Luotolahti, M., Hartiala, J., & Airaksinen, J. K. E. (2006) · EP Europace · doi:10.1093/europace/eul034 · Cited by 5
Eplerenone–A novel Mineralocorticoid receptor antagonist for the clinical application
Wu, N., Zhang, Y.-Y., & Zhao, D. (2022) · Environmental Disease · doi:10.4103/ed.ed_7_21 · Cited by 4
Outcome of pharmacological rhythm control for new-onset persistent atrial fibrillation in patients with systolic heart failure: a comparison with patients with normal left ventricular function
Hemels, M. E. W., Wiesfeld, A. C. P., van Veldhuisen, D. J., van den Berg, M. P., & Gelder, I. C. V. (2007) · EP Europace · doi:10.1093/europace/eum011 · Cited by 4
Hypertrophie ventriculaire gauche au cours de l’insuffisance rénale chronique : prévalence et facteurs de risque
Kara, L., Abbou, A., Grari, R., Regagba, D., & Benmansour, M. (2018) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2018.07.198 · Cited by 4
New oral anticoagulants and prevention of thromboembolic events in patients with hypertension and atrial fibrillation
Borghi, C., Paolillo, S., Cicero, A. F. G., Gargiulo, P., Trimarco, B., & Filardi, P. P. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000001228 · Cited by 4
Atrial electromechanical duration prolongs in patients with erectile dysfunction
Altunkol, A., Topuz, A. N., Genç, Ö., Alma, E., & Topuz, M. (2019) · The Aging Male · doi:10.1080/13685538.2019.1650336 · Cited by 4
On-treatment HDL cholesterol predicts incident atrial fibrillation in hypertensive patients with left ventricular hypertrophy
Okin, P. M., Hille, D. A., Wachtell, K., Kjeldsen, S. E., Julius, S., & Devereux, R. B. (2020) · Blood Pressure · doi:10.1080/08037051.2020.1782171 · Cited by 4
Self-citation
Terapia anticoagulante en fibrilación auricular
Prieto, S., Young, P., Ceresetto, J. M., & Bullorsky, E. O. (2011) · Medicina-buenos Aires · Cited by 4
Non-antiarrhythmic medications for atrial fibrillation: From bench to clinical practice
Guglin, M. E., Garcia, M., Yarnoz, M. J., & Curtis, A. B. (2008) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-008-9204-7 · Cited by 4
Inhibition of Inward Rectifier K+ Currents by Angiotensin II in Rat Atrial Myocytes: Lack of Effects in Cells from Spontaneously Hypertensive Rats
Sonoyama, K., Ninomiya, H., Igawa, O., Kaetsu, Y., Furuse, Y., Hamada, T., Miake, J., Li, P., Yamamoto, Y., Oginö, K., et al. (2006) · Hypertension Research · doi:10.1291/hypres.29.923 · Cited by 4
Atrial fibrillation: Pathophysiology and current therapy
Miyazaki, S., Shah, A. J., Scherr, D., & Haı̈ssaguerre, M. (2011) · Annals of Medicine · doi:10.3109/07853890.2011.554426 · Cited by 4
Atrial Fibrillation (AF) and Heart Failure (HF): To Treat the AF, be Sure to Treat the HF
Prudente, L. A. (2008) · Progress in Cardiovascular Nursing · doi:10.1111/j.1751-7117.2008.00007.x · Cited by 4
Irbesartan-mediated AT 1 receptor blockade attenuates hyposmotic-induced enhancement of I Ks current and prevents shortening of action potential duration in atrial myocytes
Wu, J., Ding, W., Zhao, J. H., Zang, W., Matsuura, H., & Horie, M. (2013) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320312474855 · Cited by 4
Combination therapy of renin angiotensin system inhibitors and bepridil is useful for maintaining sinus rhythm in patients with atrial fibrillation.
Kawamura, M., Ito, H., Onuki, T., Miyoshi, F., Minoura, Y., Asano, T., Tanno, K., & Kobayashi, Y. (2007) · PubMed · Cited by 4
Perioperative Critical Care Cardiology
Atlee, J. L., Gullo, A., Sinagra, G., & Vincent, J. (2007) · Springer eBooks · doi:10.1007/978-88-470-0558-7 · Cited by 4
Targeting angiotensin II type I receptors to reduce the risk of stroke in patients with hypertension
Papadopoulos, D. P., & Papademetriou, V. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.2.231 · Cited by 4
Complications of hypertension and the role of angiotensin receptor blockers in hypertension trials
Flaa, A., Aksnes, T. A., Strand, A. H., & Kjeldsen, S. E. (2007) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.5.3.451 · Cited by 4
Self-citation
Prévention des accidents vasculaires cérébraux dans la fibrillation auriculaire non valvulaire
Éderhy, S., Meuleman, C., Hammoudi, N., Janower, S., Boccara, F., & Cohen, A. A. (2005) · La Presse Médicale · doi:10.1016/s0755-4982(05)84180-6 · Cited by 4
p300 upregulates Ikur in atrial cardiomyocytes through activating NLRP3 inflammasome in hypertension
Zeng, L., Liu, P., Rao, F., Du, Z., Xiao, H., Yu, S., Deng, C., Zhang, M., Liu, F., Zhu, R., et al. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003501 · Cited by 3
Safety and efficacy of anticoagulant administration in people with atrial fibrillation and advanced chronic kidney disease
Irlik, K., Kwiendacz, H., Ignacy, W., Grabska, A., Gumprecht, J., Lip, G. Y. H., & Nabrdalik, K. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2574492 · Cited by 3
Association between types of antihypertensive medication and the risk of atrial fibrillation: a nationwide population study
Choi, J., Lee, S., Choi, E., Lee, K., Ahn, H., Kwon, S., Kim, B., Han, K., Oh, S., & Lip, G. Y. H. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1372505 · Cited by 3
Meta-analysis of renin angiotensin aldosterone modulators mitigating atrial fibrillation risk in hypertensive patients
Mahadevan, A., Garikipati, S., Vanani, S., Sundaram, D. M., Thompson‐Edwards, A., Reyaz, N., Babu, K., Rajarajan, S., Dhavapalani, D., Anand, D. P., et al. (2024) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2024.07.016 · Cited by 3
Fibrilación auricular en el anciano. Ese largo camino…
Urrútia, A., & Santesmases, J. (2011) · Medicina Clínica · doi:10.1016/j.medcli.2011.06.013 · Cited by 3
The Influence of Atrial Fibrillation on Cardiac Resynchronization Therapy
Centurión, O. A. (2014) · Journal of Cardiology & Current Research · doi:10.15406/jccr.2014.01.00008 · Cited by 3
Medikamentvalg ved hypertensjon
Schultz, M., Aksnes, T. A., Høieggen, A., & Kjeldsen, S. E. (2013) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.13.0311 · Cited by 3
Self-citation
Angiotensin II receptor blockers in the prevention of atrial fibrillation
Barra, S., Silvestri, N., Vitagliano, G., Madrid, A., & Gaeta, G. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902973736 · Cited by 3
A Peek at AF Myocardial Substrate Through the Signal‐Averaged ECG?
Cosío, F. G. (2007) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2007.00920.x · Cited by 3
Atrial fibrillation: Challenges and opportunities
Hersi, A. S., Mitchell, L. B., & Wyse, D. G. (2006) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(06)70998-9 · Cited by 3
LIFE (losartan intervention for endpoint reduction in hypertension) study and its substudies
Borghi, C., & Ertek, S. (2007) · International Congress Series · doi:10.1016/j.ics.2007.03.014 · Cited by 3
Future Directions in Antiarrhythmic Drug Therapy for Atrial Fibrillation
Musco, S., Seltzer, J. H., & Kowey, P. R. (2006) · Future Cardiology · doi:10.2217/14796678.2.5.545 · Cited by 3
Hemmstoffe des Renin-Angiotensin-Systems
Weber, F., & Anlauf, M. (2017) · Springer eBooks · doi:10.1007/978-3-662-54630-7_8 · Cited by 3

Authors: Wachtell, K., Lehto, M., Gerdts, E., Olsen, M. H., Hornestam, B., Dahlöf, B., Ibsen, H., Julius, S., Kjeldsen, S. E., Lindholm, L. H., Nieminen, M. S., & Devereux, R. B.
Affiliations: Cornell University (US)
Helsinki University Hospital (FI)
Haukeland University Hospital (NO)
Glostrup Hospital (DK)
Sahlgrenska University Hospital (SE)
University of Michigan (US)
Oslo University Hospital (NO)
University Hospital of Umeå (SE)
Corresponding author: Wachtell, Kristian
ORCID: Wachtell, Kristian
Lehto, Mika
Gerdts, Eva
Olsen, Michael H.
Hornestam, Björn
Kjeldsen, Sverre E.
Lindholm, Lars H.
Nieminen, Markku S.
Devereux, Richard B.
Venue: Journal of the American College of Cardiology
Publisher: Elsevier BV
Published: 2005-03
Volume: 45
Issue: 5
Pages: 712-719
ISSN: 0735-1097 (ISSN-L)
DOI: 10.1016/j.jacc.2004.10.068
OpenAlex: W2147918774
Cited by: 826
References: 27
Citations by year: 2026: 9 · 2025: 18 · 2024: 16 · 2023: 17 · 2022: 13 · 2021: 20 · 2020: 20 · 2019: 16 · 2018: 30 · 2017: 32 · 2016: 31 · 2015: 29 · 2014: 36 · 2013: 40 · 2012: 33
FWCI: 64.95
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 3096 d)
Locations: Journal of the American College of Cardiology (publishedVersion)
PubMed (publishedVersion)
Funders: Rigshospitalet
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
Keywords: angiotensin II receptor blockade, losartan, atenolol, beta-blockers, stroke prevention, hypertension, left ventricular hypertrophy, antihypertensive therapy, heart failure hospitalization, cardiovascular events, life studies, sinus rhythm maintenance, RAS inhibition, renin-angiotensin system
MeSH terms: Adrenergic beta-Antagonists, Aged, Aged, 80 and over, Atenolol, Atrial Fibrillation, Cause of Death, Double-Blind Method, Female, Humans, Hypertension, Male, Middle Aged, Prospective Studies, Risk Factors, Survival Rate, Hypertrophy, Left Ventricular, Losartan, Stroke, Angiotensin II Type 1 Receptor Blockers, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks